Starget’s proprietary in silico, AI-driven platform is designed to accelerate the discovery and development of novel radioligand therapies (RLT) across a broad range of cancer targets. By leveraging computational modeling and data-driven prediction, the platform enables Starget to rapidly identify and optimize peptide-based ligands, select appropriate radioisotopes, and prioritize candidates with the highest probability of clinical success, maximizing speed and efficiency.

The collaboration with CMIT will provide the downstream capabilities required to advance these AI-selected candidates through preclinical validation and into early-phase clinical development. The collaboration will leverage CMIT’s integrated infrastructure, including molecular imaging, radiochemistry, preclinical and clinical research, and radiopharmaceutical manufacturing and distribution.

“By pairing Starget’s in silico discovery capabilities with CMIT’s translational and manufacturing expertise, we create a highly efficient end-to-end development pathway for radiopharmaceuticals,” said Stephen Lokitz, Ph.D., Executive Director of CMIT. “This collaboration allows promising candidates to move rapidly from computational design to clinical evaluation.”